Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dermal corrosivity tests

This article was originally published in The Tan Sheet

Executive Summary

Interagency Coordinating Committee on Validation of Alternative Methods releases final recommendations accepting three animal alternative methods to test dermal corrosivity, National Institute of Environmental Health Sciences announces in 1July 31 Federal Register notice. Expedited review of EpiDerm, EPISKIN and Rat Skin Transcutaneous Electrical Resistance tests was initiated following endorsement by European Centre for the Validation of Alternative Methods Scientific Advisory Committee. ICCVAM recommends the three tests can be used to measure dermal corrosivity in a "weight-of-evidence approach using an integrated testing scheme"...

You may also be interested in...

ICCVAM/ECVAM Early Collaboration Explored To Hasten Animal Alternatives

Faster validation of animal alternative test methods is dependent upon increased collaboration between the Interagency Coordinating Committee for the Validation of Alternative Methods and the European Centre for the Validation of Alternative Methods, according to leaders of both groups

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts